Can donors with prior hepatitis be safely used for heart transplantation?

被引:7
作者
Mawhorter, Steven D. [1 ]
Avery, Robin K. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Infect Dis, Cleveland, OH 44195 USA
关键词
D O I
10.1016/j.healun.2006.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Heart transplantation represents a significant life-saving and increased quality-of-life intervention for patients with refractory cardiac failure. Successful transplantation requires continuous immunosuppression to avoid immune rejection. Unfortunately, persistent viral infections in donors may be transmitted to recipients in the process of heart transplantation. With the severe shortage of available organs and significant waiting list mortality there is a rationale for considering use of organs from donors with evidence of prior hepatitis B and/or hepatitis C infection. Methods: Published literature articles were searched using Medline,. PaperChase and further review of references in relevant articles on issues related to hepatitis B and hepatitis C and heart transplantation. Results: Donor and recipient testing for hepatitis B and hepatitis C is important for relative risk assessment. Nucleic acid testing for hepatitis B DNA and hepatitis C RNA represent emerging technologies, which may add valuable information to traditional serologic testing. Conclusions: Heart transplant recipient risk may be modified by vaccination against hepatitis B before transplantation. There is currently no available vaccine for hepatitis C. Recently described effective treatments for hepatitis B and hepatitis C provide further rationale for reconsideration of using hearts from donors with evidence of hepatitis B and/or hepatitis C infection.
引用
收藏
页码:805 / 813
页数:9
相关论文
共 60 条
[1]   Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia [J].
Agnello, V ;
Abel, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (11) :2007-2015
[2]  
Arbustini E, 1997, G Ital Cardiol, V27, P985
[3]   Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients [J].
Avery, RK .
CURRENT OPINION IN CARDIOLOGY, 1998, 13 (02) :122-129
[4]   Prophylactic measures in the solid-organ recipient before transplantation [J].
Avery, RK ;
Ljungman, P .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S15-S21
[5]   Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. [J].
Benhamou, Y ;
Tubiana, R ;
Thibault, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :177-178
[6]   Outcome of heart transplantation in patients previously infected with hepatitis C virus [J].
Castella, M ;
Tenderich, G ;
Koerner, MM ;
Arusoglu, L ;
El-Banayosy, A ;
Schulz, U ;
Schulze, B ;
Minami, K ;
Koerfer, R .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (05) :595-598
[7]   Treatment of hepatitis C in solid organ transplantation [J].
Chan, SE ;
Schwartz, JM ;
Rosen, HR .
DRUGS, 2004, 64 (05) :489-498
[8]   OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS [J].
CHAZOUILLERES, O ;
MAMISH, D ;
KIM, M ;
CAREY, K ;
FERRELL, L ;
ROBERTS, JP ;
ASCHER, NL ;
WRIGHT, TL .
LANCET, 1994, 343 (8890) :142-146
[9]   Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor [J].
Chung, RT ;
Feng, S ;
Delmonico, FL .
AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (02) :185-191
[10]  
Dal Bello B, 1998, TRANSPL P, V30, P2086